A number of other equities research analysts have also commented on ALNY. FBR & Co started coverage on shares of Alnylam Pharmaceuticals in a report on Monday, October 30th. They set a buy rating and a $150.00 price objective on the stock. B. Riley initiated coverage on shares of Alnylam Pharmaceuticals in a research note on Wednesday, November 1st. They issued a buy rating and a $240.00 price target on the stock. Piper Jaffray Companies reiterated an overweight rating and issued a $14.71 price target (down from $188.00) on shares of Alnylam Pharmaceuticals in a research note on Thursday, November 2nd. Needham & Company LLC reiterated a buy rating and issued a $152.00 price target (up from $125.00) on shares of Alnylam Pharmaceuticals in a research note on Friday, November 3rd. Finally, Cowen reiterated an outperform rating and issued a $151.00 price target (up from $117.00) on shares of Alnylam Pharmaceuticals in a research note on Friday, November 3rd. Three investment analysts have rated the stock with a sell rating, seven have given a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the stock. Alnylam Pharmaceuticals currently has a consensus rating of Buy and an average target price of $126.98.
Shares of Alnylam Pharmaceuticals (ALNY) opened at $115.92 on Friday. Alnylam Pharmaceuticals has a twelve month low of $44.50 and a twelve month high of $147.63. The company has a current ratio of 9.83, a quick ratio of 9.83 and a debt-to-equity ratio of 0.14.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings data on Thursday, February 8th. The biopharmaceutical company reported ($1.48) EPS for the quarter, missing analysts’ consensus estimates of ($1.38) by ($0.10). Alnylam Pharmaceuticals had a negative return on equity of 48.88% and a negative net margin of 545.95%. The company had revenue of $37.90 million for the quarter, compared to analyst estimates of $19.31 million. During the same quarter in the previous year, the business earned ($1.32) earnings per share. The company’s revenue was up 116.6% on a year-over-year basis. equities analysts expect that Alnylam Pharmaceuticals will post -5.69 earnings per share for the current year.
In related news, VP Michael Mason sold 36,745 shares of Alnylam Pharmaceuticals stock in a transaction dated Thursday, January 4th. The shares were sold at an average price of $131.59, for a total transaction of $4,835,274.55. Following the completion of the sale, the vice president now owns 6,352 shares of the company’s stock, valued at approximately $835,859.68. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Laurie Keating sold 6,249 shares of Alnylam Pharmaceuticals stock in a transaction dated Wednesday, December 20th. The stock was sold at an average price of $121.20, for a total transaction of $757,378.80. Following the sale, the senior vice president now directly owns 17,749 shares of the company’s stock, valued at approximately $2,151,178.80. The disclosure for this sale can be found here. Insiders have sold a total of 220,409 shares of company stock worth $28,667,017 over the last 90 days. 4.30% of the stock is owned by company insiders.
Several hedge funds have recently made changes to their positions in the stock. The Manufacturers Life Insurance Company boosted its holdings in shares of Alnylam Pharmaceuticals by 7.0% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 2,541 shares of the biopharmaceutical company’s stock worth $203,000 after buying an additional 167 shares during the period. Prudential Financial Inc. boosted its holdings in shares of Alnylam Pharmaceuticals by 4.8% during the 2nd quarter. Prudential Financial Inc. now owns 4,404 shares of the biopharmaceutical company’s stock worth $351,000 after buying an additional 200 shares during the period. Dimensional Fund Advisors LP boosted its holdings in shares of Alnylam Pharmaceuticals by 0.4% during the 3rd quarter. Dimensional Fund Advisors LP now owns 180,058 shares of the biopharmaceutical company’s stock worth $21,156,000 after buying an additional 629 shares during the period. Great West Life Assurance Co. Can boosted its holdings in shares of Alnylam Pharmaceuticals by 8.5% during the 3rd quarter. Great West Life Assurance Co. Can now owns 8,904 shares of the biopharmaceutical company’s stock worth $1,050,000 after buying an additional 695 shares during the period. Finally, Nisa Investment Advisors LLC boosted its holdings in shares of Alnylam Pharmaceuticals by 10.8% during the 4th quarter. Nisa Investment Advisors LLC now owns 7,200 shares of the biopharmaceutical company’s stock worth $915,000 after buying an additional 700 shares during the period. 88.59% of the stock is owned by institutional investors and hedge funds.
WARNING: This report was first published by The Lincolnian Online and is owned by of The Lincolnian Online. If you are reading this report on another site, it was illegally stolen and reposted in violation of United States & international copyright & trademark laws. The legal version of this report can be viewed at https://www.thelincolnianonline.com/2018/02/12/jefferies-group-analysts-give-alnylam-pharmaceuticals-alny-a-156-00-price-target.html.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.